Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
EDAP's Cash to Debt is ranked higher than
96% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. EDAP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
EDAP' s 10-Year Cash to Debt Range
Min: 0.37  Med: 9999.00 Max: No Debt
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -11.79
EDAP's Operating margin (%) is ranked lower than
63% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. EDAP: -11.79 )
Ranked among companies with meaningful Operating margin (%) only.
EDAP' s 10-Year Operating margin (%) Range
Min: -43.96  Med: -14.49 Max: -2.5
Current: -11.79
-43.96
-2.5
Net-margin (%) -14.72
EDAP's Net-margin (%) is ranked lower than
64% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. EDAP: -14.72 )
Ranked among companies with meaningful Net-margin (%) only.
EDAP' s 10-Year Net-margin (%) Range
Min: -53.64  Med: -18.59 Max: 42.97
Current: -14.72
-53.64
42.97
ROE (%) -32.52
EDAP's ROE (%) is ranked lower than
71% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. EDAP: -32.52 )
Ranked among companies with meaningful ROE (%) only.
EDAP' s 10-Year ROE (%) Range
Min: -111.74  Med: -19.67 Max: 44.99
Current: -32.52
-111.74
44.99
ROA (%) -22.88
EDAP's ROA (%) is ranked lower than
68% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. EDAP: -22.88 )
Ranked among companies with meaningful ROA (%) only.
EDAP' s 10-Year ROA (%) Range
Min: -31.62  Med: -11.77 Max: 25.67
Current: -22.88
-31.62
25.67
ROC (Joel Greenblatt) (%) -22.54
EDAP's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. EDAP: -22.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EDAP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -86.63  Med: -34.32 Max: 110.27
Current: -22.54
-86.63
110.27
Revenue Growth (3Y)(%) -14.00
EDAP's Revenue Growth (3Y)(%) is ranked lower than
82% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. EDAP: -14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EDAP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.3  Med: -1.40 Max: 11
Current: -14
-17.3
11
EBITDA Growth (3Y)(%) -43.90
EDAP's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. EDAP: -43.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EDAP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.5  Med: -37.00 Max: 157.1
Current: -43.9
-66.5
157.1
EPS Growth (3Y)(%) -35.50
EDAP's EPS Growth (3Y)(%) is ranked lower than
84% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. EDAP: -35.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EDAP' s 10-Year EPS Growth (3Y)(%) Range
Min: -36.7  Med: -16.25 Max: 241.1
Current: -35.5
-36.7
241.1
» EDAP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

EDAP Guru Trades in Q2 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q3 2014

EDAP Guru Trades in Q3 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q4 2014

EDAP Guru Trades in Q4 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q1 2015

EDAP Guru Trades in Q1 2015

Robert Bruce 1,565,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 80.65
EDAP's Forward P/E is ranked lower than
90% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. EDAP: 80.65 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.82
EDAP's P/B is ranked lower than
77% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.13 vs. EDAP: 5.82 )
Ranked among companies with meaningful P/B only.
EDAP' s 10-Year P/B Range
Min: 0.5  Med: 2.45 Max: 18.2
Current: 5.82
0.5
18.2
P/S 2.55
EDAP's P/S is ranked higher than
57% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. EDAP: 2.55 )
Ranked among companies with meaningful P/S only.
EDAP' s 10-Year P/S Range
Min: 0.37  Med: 1.29 Max: 6
Current: 2.55
0.37
6
Current Ratio 2.23
EDAP's Current Ratio is ranked lower than
57% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. EDAP: 2.23 )
Ranked among companies with meaningful Current Ratio only.
EDAP' s 10-Year Current Ratio Range
Min: 1.27  Med: 2.35 Max: 3.92
Current: 2.23
1.27
3.92
Quick Ratio 2.23
EDAP's Quick Ratio is ranked higher than
53% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. EDAP: 2.23 )
Ranked among companies with meaningful Quick Ratio only.
EDAP' s 10-Year Quick Ratio Range
Min: 1.07  Med: 2.16 Max: 3.51
Current: 2.23
1.07
3.51
Days Inventory 67.51
EDAP's Days Inventory is ranked higher than
85% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.50 vs. EDAP: 67.51 )
Ranked among companies with meaningful Days Inventory only.
EDAP' s 10-Year Days Inventory Range
Min: 95.66  Med: 118.54 Max: 298.9
Current: 67.51
95.66
298.9
Days Sales Outstanding 117.18
EDAP's Days Sales Outstanding is ranked lower than
82% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. EDAP: 117.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDAP' s 10-Year Days Sales Outstanding Range
Min: 77.32  Med: 173.92 Max: 249.93
Current: 117.18
77.32
249.93

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.82
EDAP's Price/Tangible Book is ranked lower than
60% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.53 vs. EDAP: 5.82 )
Ranked among companies with meaningful Price/Tangible Book only.
EDAP' s 10-Year Price/Tangible Book Range
Min: 0.22  Med: 2.33 Max: 16.68
Current: 5.82
0.22
16.68
Price/Median PS Value 1.98
EDAP's Price/Median PS Value is ranked lower than
86% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. EDAP: 1.98 )
Ranked among companies with meaningful Price/Median PS Value only.
EDAP' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 0.73 Max: 4.65
Current: 1.98
0.26
4.65
Earnings Yield (Greenblatt) (%) -2.80
EDAP's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. EDAP: -2.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EDAP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 3.25 Max: 156434.3
Current: -2.8
1.1
156434.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EDA.Germany,
Edap TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS. Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2013, the HIFU division's patent portfolio contained 36 patents consisting of 16 in the United States, 18 in the European Union and Japan and 2 in Israel and the rest of the world. They belong to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. The Company and its products are regulated in the United States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act.
» More Articles for EDAP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
8:31 am EDAP TMS SA announces that Eric Soyer CFO has resigned to accept a top management position... Jul 05 2015
EDAP Announces Senior Management Transition Jul 02 2015
EDAP Announces Focal One(R) HIFU Installation at Germany's Martini-Klinik Jun 09 2015
Thursday's After-Hours Movers: GameStop, Deckers Outdoor And More May 28 2015
EDAP Reports First Quarter 2015 Results May 12 2015
Q1 2015 Edap Tms SA Earnings Release - After Market Close May 12 2015
EDAP to Report First Quarter 2015 Results on May 13, 2015 May 06 2015
EDAP TMS SA Financials Apr 08 2015
Friday's Morning Movers: Earnings Start To Trickle In Jan 09 2015
EDAP Reports Continued Strong Growth in Third Quarter 2014 Nov 20 2014
EDAP Receives FDA Guidance on PMA for Ablatherm-HIFU Nov 06 2014
EDAP to Report Third Quarter 2014 Results on November 20, 2014 Nov 04 2014
EDAP Announces Sale of Focal One(R) HIFU Device to Nantes-Atlantis Urology Clinic in France Oct 21 2014
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action against EDAP TMS S.A. and... Sep 29 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A.... Sep 25 2014
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of EDAP TMS S.A. Of Upcoming Deadline Sep 18 2014
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of EDAP TMS S.A. Sep 05 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In... Aug 29 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A.... Aug 29 2014
Investors of EDAP TMS S.A. With Losses of $50,000 or More Are Encouraged to Contact Law Offices of... Aug 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK